Main description:

The 26th edition provides practical, evidence-based recommendations from the experts in antimicrobial therapy for treatment of infectious diseases in children. For each disease, the authors provide a commentary to help health care providers select the best of all antimicrobial choices.

Drug descriptions cover pediatric-appropriate antimicrobial agents available today and include complete information about dosing regimens.

New in the 26th edition:

First pediatric approval of beta-lactam/beta-lactamase inhibitor for CRE (carbapenem-resistant enteric bacilli), ceftazidime-avibactam
Replacement antibiotics for cefotaxime (lack of availability in the US), including ceftriaxone and cefepime (for neonates)
Situations in which ceftaroline is preferred over vancomycin by the Editors for MRSA infections
Updates on management of influenza, including baloxavir (now approved for children >12 years)
New approaches to treatment of mucomycosis
New recommendations for malaria
More than 150 new references!

Contents:

Notable Changes to 2020 Nelson's Pediatric Antimicrobial Therapy, 26th Edition
1. Choosing Among Antibiotics Within a Class: Beta-lactams and Beta-lactamase Inhibitors, Macrolides, Aminoglycosides, and Fluoroquinolones
2. Choosing Among Antifungal Agents: Polyenes, Azoles, and Echinocandins
3. How Antibiotic Dosages Are Determined Using Susceptibility Data, Pharmacodynamics, and Treatment Outcomes
4. Approach to Antibiotic Therapy of Drug-Resistant Gram-negative Bacilli and Methicillin-Resistant Staphylococcus aureus
5. Antimicrobial Therapy for Newborns
A. Recommended Therapy for Selected Newborn Conditions
B. Antimicrobial Dosages for Neonates
C. Aminoglycosides
D. Vancomycin
E. Use of Antimicrobials During Pregnancy or Breastfeeding
6. Antimicrobial Therapy According to Clinical Syndromes
A. Skin and Soft Tissue Infections
B. Skeletal Infections
C. Eye Infections
D. Ear and Sinus Infections
E. Oropharyngeal Infections
F. Lower Respiratory Tract Infections
G. Cardiovascular Infections
H. Gastrointestinal Infections
I. Genital and Sexually Transmitted Infections
J. Central Nervous System Infections
K. Urinary Tract Infections
L. Miscellaneous Systemic Infections
7. Preferred Therapy for Specific Bacterial and Mycobacterial Pathogens
A. Common Bacterial Pathogens and Usual Pattern of Susceptibility to Antibiotics (Gram Positive)
B. Common Bacterial Pathogens and Usual Pattern of Susceptibility to Antibiotics (Gram Negative)
C. Common Bacterial Pathogens and Usual Pattern of Susceptibility to Antibiotics (Anaerobes)
D. Preferred Therapy for Specific Bacterial and Mycobacterial Pathogens
8. Preferred Therapy for Specific Fungal Pathogens
A. Overview of More Common Fungal Pathogens and Their Usual Pattern of Antifungal Susceptibilities
B. Systemic Infections
C. Localized Mucocutaneous Infections
9. Preferred Therapy for Specific Viral Pathogens
A. Overview of Non-HIV, Non-Hepatitis B or C Viral Pathogens and Usual Pattern of Susceptibility to Antivirals
B. Overview of Hepatitis B or C Viral Pathogens and Usual Pattern of Susceptibility to Antivirals
C. Preferred Therapy for Specific Viral Pathogens
10. Preferred Therapy for Specific Parasitic Pathogens
A. Selected Common Pathogenic Parasites and Suggested Agents for Treatment
B. Preferred Therapy for Specific Parasitic Pathogens
11. Alphabetic Listing of Antimicrobials
A. Systemic Antimicrobials With Dosage Forms and Usual Dosages
B. Topical Antimicrobials (Skin, Eye, Ear, Mucosa)
12. Antibiotic Therapy for Children Who Are Obese
13. Sequential Parenteral-Oral Antibiotic Therapy (Oral Step-down Therapy) for Serious Infections
14. Antimicrobial Prophylaxis/Prevention of Symptomatic Infection
A. Postexposure Antimicrobial Prophylaxis to Prevent Infection
B. Long-term Antimicrobial Prophylaxis to Prevent Symptomatic New Infection
C. Prophylaxis of Symptomatic Disease in Children Who Have Asymptomatic Infection/Latent Infection
D. Surgical/Procedure Prophylaxis
Appendix: Nomogram for Determining Body Surface Area
References
Index